uPA/uPAR系统在子宫内膜异位症病程进展中的作用

Role of the uPA/uPAR System in the Progression of Endometriosis

子宫内膜异位症(EMs)是一种常见的雌激素依赖的良性疾病,指子宫内膜组织异位种植在子宫腔被覆黏膜及子宫肌层以外的部位,最常种植于盆腔脏器和腹膜,以侵犯卵巢最为常见。尿激酶型纤溶酶原激活物(uPA)/尿激酶型纤溶酶原激活物受体(uPAR)系统由uPA、uPAR以及纤溶酶原激活物抑制物共同组成,可激活纤溶酶原,还可参与细胞外基质降解、新生血管形成以及信号转导,在一定程度上为在位内膜的黏附及转移、异位内膜的生长及侵袭提供条件,促进EMs的病程进展。

Endometriosis(EMs)is a common estrogen-dependent gynecologic disorder in which endometrial tissue is found at locations outside the uterine endometrium and myometrium,with the most common implantation in pelvic viscera and peritoneum,and the most common invasion of ovary.The urokinase-type plasminogen activator(uPA)/urokinase-type plasminogen activator receptor(uPAR)system consists of uPA,uPAR,and plasminogen activator inhibitors,which activates plasminogen and is involved in extracellular matrix degradation,neovascularization and signal transduction,providing conditions for adhesion and metastasis of ectopic endometrium,growth and invasion of ectopic endometrium,thus promoting the progression of EMs.